THE STATE OF HIV PREVENTION IN MOZAMBIQUE

2020

The number of adults newly infected with HIV declined from 130,000 in 2010 to 120,000 in 2019, a 9% decline.

Number of new HIV infections (215 years)

HIV prevalence

Proportion of women who experienced intimate partner violence

HIV prevention adaptations during COVID-19

Policy and structural barriers

Key populations

Criminalization of the behaviour of key populations

The national strategy includes critical elements of the programme package for key populations

Avoided health care because of stigma and discrimination

Adolescent girls and young women

Proportion of women who experienced intimate partner violence

Girls who completed lower secondary education

Condom use at last anal sex (%)

Condom use with a non-regular partner 15–49 years (%)

Pre-exposure prophylaxis

PrEP

Pre-Exposure Prophylaxis (PrEP)

Number of people actively taking Pre-Exposure Prophylaxis (PrEP)

Antiretroviral drug-based prevention

Coverage of antiretroviral drug-based prevention targets was moderate and progress against targets was 41% of annual targets in 2018, 42% in 2019, and 44% in 2020.

Levels of suppression are high overall. Based on limited available data, treatment coverage among key populations is not known.

Data sources: UNAIDS 2020 HIV estimates; Global AIDS Monitoring 2020; Global HIV Prevention Coalition progress survey 2020; and ICF – the DHS Program STATcompiler.

Implementation of Prevention 2020 Roadmap

Target: 50% (take home dosages)

Note: 'Yes' refers to the adoption having been introduced (but necessarily, it being universally available).

Note: 'No' refers to the adaptation having been introduced.

Linkages between HIV and sexual and reproductive health services

HIV testing services integrated within sexual and reproductive health

Provider-initiated condom promotion in family planning services

Percentage of women who experienced intimate partner violence among young people 15–24 years old (%)

Condom use, completion of lower-secondary education, and coverage of opioid substitution therapy is very low.